The Biosimilars Europe Congress 2016 is dedicated to latest Development in Biosimilars and the BREXIT Implications.
The Biosimilars Europe Congress 2016 covers topics such as:
- Challenges faced when moving towards globalization
- Current status of Biosimliars market
- IP issues
- Opportunities in emerging markets
- Partnership
- Naming and labeling issues related to biosimilars
- Challenges and opportunities for biobetters and monoclonal antibody biosimilars
- New investment and business models
- Benefits and concerns of interchangeable and biosubstitutes and post authorization monitoring
- Clinical trials strategies and new guidelines for biosimilar clinical trials
- New solutions to demonstrate similarity and different characterization methods
- Bringing biosimilars closer to patients and healthcare professionals
- BREXIT Implications
The Biosimilars Europe Congress 2016 brings together senior attendees from:
- Clinical Development
- Biosimilar Development
- Commercial Development
- Global Strategy
- Biosimilar Analysis
- Biologics Regulation
- Regulatory Affairs
- Medical Affairs
- Regulatory Compliance
- Biobetter Development
- Biosimilar Process Development
- Biologics Development
- Follow-On Biologics
- Biosuperiors Portfolio Management
- Legal Affairs Strategic Marketing
- Strategic Planning
- Research & Development
- Commercial Affairs and Development
- Pharmacovigilance
- Market Access
- SBMP
- Market Entry